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Abstract
Objective: To develop statistical tools that utilize combined initial survival data and postresuscitation survival data to test the null hypothesis that true, population-wide outcomes
following experimental CPR interventions are not different from control.
Method: A new test statistic, d2 , for evaluating Type 1 error is derived from a bivariate,
two-dimensional analysis of categorical initial resuscitation and post-resuscitation survival
data, which are statistically independent because they are obtained during non-overlapping
periods of time. The d2 test statistic, which is distributed as a chi-squared distribution, is
derived from first principles and validated using Monte Carlo methods of computer
simulation for thousands of clinical trials.
Results: Under the null hypothesis, the normalized difference in the proportions of
patients surviving the initial resuscitation period and the normalized difference in the
proportions of such short-term survivors that also survive the post-resuscitation period are
jointly distributed in a two-dimensional space as a bivariate standard normal distribution,
against which observed intervention and control outcomes can be compared in a test of
statistical significance. Typically this two-dimensional approach has greater statistical
power to detect true differences, compared to conventional one-dimensional tests. Smaller
group sizes (Ns) are usually required to reach statistical significance when both initial
survival and post-resuscitation survival are considered together. Such two-dimensional
analysis is easily extended to meta-analysis of multiple trials.
Conclusions: A straightforward, easy-to-use bivariate test for Type I errors in statistical
inference can be done for resuscitation studies reporting both short-term and long-term
survival data. Acceptance of such two-dimensional tests of the null hypothesis, as
proposed by Hallstrom, can save time, money, effort, and disappointment in the difficult
and sometimes frustrating field of resuscitation research.
Key words: Cardiopulmonary resuscitation (CPR); Clinical trials, Device; Drug Therapy,
Meta-analysis, Methodology, Statistical analysis.

1. Introduction
In a typical clinical study of a new resuscitation device or method victims of cardiac arrest
are randomized to experimental care (the intervention group) and to standard care (the
control group). Some measure of outcome, typically survival, is recorded as a categorical
end-point. The fractions or percentages of survivors in the intervention group and in the
control group are compared for statistical significance. Survival is usually reported both
after initial return of spontaneous circulation (ROSC, or short-term survival) and after 24
hours, hospital discharge, or some time after hospital discharge (long-term survival). The
numbers of patients surviving long-term tend to be small. Members of the resuscitation
research community have debated for years the merits of powering studies for short-term
survival versus long-term survival. Ideally one would want to see the virtues of proposed
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improvements documented by studies demonstrating improved long-term, neurologically
intact survival1, 2. No one advocates developing methods that resuscitate hearts but not
brains, leaving victims in lingering vegetative states. Yet the awful realities of current
long-term survival rates and the unforgiving nature of the binomial distribution dictate that
many hundreds, even thousands, of patients must be randomized to achieve a significant
long-term end point in a single study.
Pragmatists worry that if all innovations must pass the test of long-term survival, the cost
of innovation would become so high that many useful improvements—especially modest,
incremental improvements—would never be realized. They retort that since the purpose of
CPR is return of spontaneous circulation, and since long-term outcome depends on many
confounding factors related to the quality of post-resuscitation intensive care, it is an
unrealistic burden to require that all innovations in CPR be tested to the gold standard of
long-term, neurologically intact survival. Many fewer patients would be required for
statistical significance if the accepted primary end point were ROSC. In turn, clinical
research could proceed much faster, ultimately benefiting more people sooner.
The problem with relying on short-term survival only was demonstrated by the experience
with high dose epinephrine (some would say any dose of epinephrine), which in animal
studies and clinical trials showed increased frequencies of ROSC, but not necessarily longterm survival.3-10 Further work documented significant toxicity in the form of postresuscitation myocardial depression and prolonged high peripheral vascular resistance.
These effects appear to decrease the chances of surviving the immediate post-resuscitation
period, negating any overall long-term benefit and perhaps diminishing the quality of life
of those who do survive. The problem in general is that some interventions that increase
short-term survival may themselves have long-term toxicity or do lasting harm. Easily
imagined examples of such harm include broken ribs, barotrauma to the lungs, myocardial
damage, infection, renal failure, hepatotoxicity, or stroke.
This paper is dedicated to the proposition that truly good innovations in CPR will increase
both ROSC and post-resuscitation survival and that this combined effect can be verified in
more enlightened and efficient statistical tests of the null hypothesis to exclude Type I
errors in statistical inference (rejecting the null hypothesis when it is true). In a recent
paper utilizing computer simulations Hallstrom11 has suggested that both short-term and
long-term survival are important outcomes and need to be considered jointly. In particular,
a bivariate, two-dimensional analysis of survival data can often produce better
discrimination of significant results with fewer patients per study group than tests of longterm survival alone. The present paper further develops this concept and presents a simple,
direct, analytical approach for two-dimensional tests of joint short-term and long-term
survival. Both types of survival data are usually reported in CPR research studies, albeit
with smaller numbers for long-term survivors, and so are readily available for analysis.
The strategy is to use all hard won clinical data available to test the null hypothesis by
explicitly considering survival in two non-overlapping epochs of time—the arrest and
resuscitation interval, and the post-resuscitation interval.
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2. Methods
2.1 Definitions
Imagine a clinical trial in which NA patients are randomized to receive standard CPR
(controls) and N B patients are randomized to receive experimental CPR. Let N 1A and N 1B
be the numbers initially resuscitated in the control and intervention groups, according to
reasonable criteria for return of spontaneous circulation (ROSC). The corresponding
observed proportions of initial survivors are p1A and p1B. Let N2A and N2B be the numbers
of patients who survive through the post-resuscitation phase and live long-term according
to a reasonable definition, such as neurologically intact hospital discharge. The
proportions of long-term survivors, as conventionally reported, are N 2A/NA and N2B/N B.
These values are readily found in the literature as the traditional gold standard end points.
For analysis we divide the trial into two non-overlapping phases in the time domain: the
initial resuscitation phase and the post-resuscitation phase. Then we introduce a new
outcome measure, which is the proportion of those initially resuscitated that also survive
long term. For control group A, p2A = N2A /N1A, if N1A > 0. For experimental group B,
p2B = N2B/N1B , if N1B > 0. The proportions p2A and p2B are measures of the probability of
surviving from the beginning of the post-resuscitation period to the end of the postresuscitation period. They are statistically independent of proportions p 1A and p1B of initial
survivors. Proportions p1 and p2 represent events in non-overlapping epochs of time. The
experiment is like rolling a die twice. Patients have to run certain risks of arrest and CPR
itself, and then, if they survive this challenge, run a second set of new and independent
risks in the post-resuscitation period.
We consider p1 and p2 to be experimental samples of the underlying true probabilities, 1
and 2 , of initial resuscitation survival and post-resuscitation survival. For example, if 1
= 2 = 1/3 for group A, then the outcome of standard CPR for any single patient could be
simulated by rolling a die. Since a normal die has 6 sides, if either one or two spots come
up on the first roll, then that would indicate short-term survival. If so, a second roll is
taken, and if either one or two spots come up on the second roll, then that would indicate
long-term survival. The observed proportions p1A and p2A are the result of repeating this
experiment NA times for group A with true probabilities 1A and 2A . Similarly for group
B, the observed proportions p1B and p2B are modeled by N B paired rolls, with perhaps
different probabilities for survival 1B and 2B.
The results will vary according to the underlying binomial probability distributions, which
have mean values  and variances  (1-)/N, where  is the true probability of survival and
N is the number of rolls. The clinical trial can be regarded as an experiment designed to
measure these true underlying probabilities 1A ,1B , 2A , and 2B of initial resuscitation
survival and post-resuscitation survival in the intervention and control groups by sampling
from four different probability distributions. The measured proportions, p 1A , ,p1B , p2A ,
and p2B provide unbiased estimates of the underlying probabilities. These sample
proportions have variances 1A (1-1A )/NA , etc., which are not known exactly at the time
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of the experiment. However, unbiased estimates of the variances are provided by
p1A (1-p1A)/(NA –1) , etc.12
2.2 Two dimensional significance testing
Using these definitions, one may compute the observed initial resuscitation and postresuscitation survival proportions, p1A, p1B, p2A , and p2B from reported outcome data for
control group A and intervention group B. All four proportions are statistically
independent. The observed differences in survival proportions between intervention and
control groups are

p1  p1B  p1A

(1a)

for initial resuscitation and

p2  p2 B  p2 A

(1b)

for survival during the post-resuscitation period.
The corresponding variance estimates based upon sample data are

ˆ 12 

p1A (1  p1A ) p1B (1  p1B )
and

NA  1
NB  1

(2a)

ˆ 22 

p 2 A (1  p 2 A ) p 2 B (1  p 2 B )
,

N1A  1
N1B  1

(2b)

where N1A  p1A N A > 1, and N1B  p1B N B > 1. Here we invoke the principle that the
variance of the sum or difference of two independent random variables is the sum of the
variances. The use of N-1 values in the denominators leads to unbiased variance
estimates12 .
Under the null hypothesis that 1A = 1B and 2A = 2B any apparent differences in
outcomes between groups A and B are the result of sampling variation of the binomial
distribution. The expected values of p1 and p2 are zero, and the variances are given
approximately by (2a) and (2b). Somewhat more stable and accurate estimates ̂12 and ̂ 22
can be obtained for the purpose of null hypothesis testing using pooled estimates for the
presumed common survival probabilities in groups A and B during each phase of the
study. These pooled estimates are p1  ( N1A  N1B ) ( N A  N B ) and

p2  ( N 2A  N 2 B ) ( N1A  N1B ) . Then refined variance estimates can be computed as
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ˆ 12 

p1 (1  p1 ) p1 (1  p1 )
and

NA  1
NB  1

(2c)

ˆ 22 

p2 (1  p2 ) p2 (1  p2 )
.

N1A  1
N1B  1

(2d)

In turn, we can define independent normalized differences in survival proportions as

z1 

p1
and
ˆ 1

(3a)

z2 

p 2
.
ˆ 2

(3b)

For NA and NB greater than, say, 20 random variables z1 and z2 are each distributed as
independent standard normal distributions with zero means and approximately unit
variances. One can show along the lines of Welch13 that z1 and z2 are each distributed very
much like a "Student" t-distribution with a number of degrees of freedom roughly equal to
twice the number of survivors in each case. For most practical cases such a Student tdistribution is equivalent to the normal distribution. In turn, to obtain a joint test of the
null hypothesis one can compute the test statistic
d 2  z12  z 22 ,

(4)

which is distributed approximately as a chi-squared distribution with two degrees of
freedom. (In general, if z1 , z 2 ,  z k are independent normally distributed random
variables, each with zero mean and unit variance, then the random variable
d 2  z12  z 22    z 2k has, by definition, a chi-squared distribution with k degrees of
freedom.)
When the simple variance estimates (2a) and (2b) are used to derive d 2, the actual
distribution of (4) will have a slightly longer "tail" than a perfect analytical chi-squared
distribution. The tail of the distribution of d2 more closely approximates the chi-squared
distribution when the refined variance estimates (2c) and (2d) are used. As the sizes of the
study groups NA and NB increase the estimates improve. One objective of the present
research is to determine by computer simulation whether for realistic Ns in resuscitation
studies, the accuracy of these estimates is sufficient.
One of the pleasing features of this approach is that there is a straightforward graphical
interpretation of the test statistic, d2. It is the square of the straight-line distance between
the origin and sample point P = (z1 , z2) in the two-dimensional z-space of Figure 1, in
which for any study z1 and z2 are plotted in a rectangular grid. Here the horizontal axis for
z1 represents the normalized difference in initial survival. The vertical axis z2 represents
the normalized difference in post-resuscitation survival. These two independent axes
6

represent two non-overlapping phases of resuscitation. Components z1 and z2 can be either
positive or negative, representing beneficial or harmful effects in each phase. Straight-line
distance, d, is the length of the vector between the origin and sample point, P = (z 1 , z2).
Length, d, is always positive or zero. Length, d, is computed from the sum of squares of z1
and z2 using the Pythagorean theorem of equation (4).
Under the null hypothesis, denoted H 0 , the probability density distribution for all possible
trial outcomes, P, in Figure 1 is binormal, centered about the origin. It has circular
contours of constant value in the z1 – z2 plane. A circular contour at approximately 2.4
units from the origin, such as that labeled H 0 in Figure 1, represents the 95 percent
confidence limit of the binormal distribution. If sample point, P, lies at the periphery of
this distribution, it is unlikely to be the result of sampling variation only. Test statistic d 2 is
a measure of the remoteness of P from the origin. The farther P is from the origin, the
smaller is the probability of making a false positive interpretation of the results—that is, a
Type I error in statistical inference.
When an alternative hypothesis, H1, is true, there is a real effect of the intervention upon
survival. Then the distribution of sample points will fall farther from the origin in the z1 –
z2 plane. Point P1 in Figure 1 represents such a result. The distribution of sample points
under H1 , also has circular contours but is centered on a point displaced from the origin by
a distance proportional to the true treatment effect.
The direction of point, P, from the origin in the z1 – z2 plane defines whether any
significant effect is good, bad, or mixed. A point such as P 1 that is clearly in the right
upper quadrant in Figure 1 represents a good effect that improves both short-term survival
and post-resuscitation survival from cardiac arrest. A point clearly in the left, lower
quadrant represents a harmful effect in both phases of resuscitation, and one located
elsewhere represents a mixed effect. Such mixed effects are biologically plausible. A
point in the right lower quadrant of the z1 – z2 plane implies short-term benefit with longerterm toxicity, rather like epinephrine. A point in the left upper quadrant implies short-term
toxicity coupled with long-term benefit, for example the action of a cytoprotective drug
that also causes hypotension when given as an intravenous bolus (e.g. deferoxamine 14).
Thus it is reasonable to employ a test statistic such as d2 to evaluate departure from the null
hypothesis in all four quadrants. The direction of point, P, from the origin indicates the
quality of the effect, and the distance of point, P, from the origin indicates its statistical
significance.
Hallstrom11 has suggested that some points in the right upper quadrant of similar plots that
are close to the horizontal (short-term) axis may not represent good outcomes from a costeffectiveness standpoint. A large increase in short-term survival, accompanied by a very
small increase in long-term survival might represent an unreasonable increase in cost,
individual suffering, and family suffering for little-long term benefit. Hallstrom's estimate
of the unacceptable cost, however, shaves only a small fraction of the area from the bottom
of the right upper quadrant, which remains largely intact.
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2.3 Monte Carlo methods
To determine if a chi-squared distribution is a reasonable approximation to the actual
distribution of d2 as defined in Equation (4), computer simulations of several million
control and experimental resuscitations were implemented in the Visual Basic
programming language within a Microsoft Excel spreadsheet. If a random number 0 < x <
1 was less than a given true probability 1, then a simulated patient was designated as
resuscitated, and in this case if a second random number 0 < x < 1 was less than a given
true probability 2, then a simulated patient was designated as long-term survivor. For
simulations of a true null there was no true difference between intervention and control
probabilities: 1 = 1A= 1B , and 2 = 2A= 2B .
To assess agreement between numerical and analytical results, distributions of d 2 test
statistics were generated for thousands of simulated clinical trials. Group Ns for each trial
ranged from 25 to 200. For each of several trial scenarios the simulated distributions of d 2
test statistics for 50,000 simulated trials was compared with the theoretical chi-squared
distribution with two degrees of freedom. To assess agreement in the critical tail regions
of the distributions the tail probability (proportion of d2 values > 6) was calculated using
both the numerical results and the analytical chi-squared distribution, for which the tail
probability is 0.0498.
2.4 Power of the analysis
Derivation of the power of the analysis is illustrated in Figure 2. Here the distribution of
the test statistic, d2, under the null hypothesis, H0 , is represented by the thin curve to the
left, and the distribution of d2 under an alternative hypothesis, H1 , of a true positive
treatment effect, is represented by the thicker curve to the right. Power may be calculated
2
2
for the d2 statistic in the usual way, given an alternative hypothesis 1   2  > 0, as
well as the associated probability density distribution for d 2 H1 , and a particular cutoff
value, c, for statistical significance of d2 in a test of the null hypothesis, for example c = 6,
which corresponds to 1-tailed P < 0.05.
The probability density distribution for d 2 H1 , is a noncentral chi-squared distribution.
The noncentral chi-squared distribution is not as well-known as the ordinary, or central,
chi-squared distribution, but it is precisely formulated and can be computed exactly15 . In
particular, if z1 , z 2 ,  z k are independent normally distributed random variables with
mean values 1 ,  2 ,   k and each with unit variance, then the random variable
d 2  z12  z 22    z 2k has, by definition, a noncentral chi-squared distribution with k
degrees of freedom and noncentrality parameter   12   22     2k . If  = 0 then we
have an ordinary, central chi-squared distribution, corresponding to the distribution of d2
under H0 . However, for alternative hypotheses we have  > 0. The mean of the noncentral
chi-squared distribution is k + , and the variance is 2(k+). Central and noncentral chi8

squared distributions for k = 2 are shown in Figure 2. In the present application for a
1  2  2  2 for true differences in
single research study k is always 2 and  
12
 22
survival proportions 1 = 1B - 1A and 2 = 2B - 2A with true variances

12 

1A (1  1A ) 1B (1  1B )
 (1  2 A ) 2 B (1  2 B )
and 22  2 A
.


1A N A
1B N B
NA
NB

Now let f(x) be the known probability density function for the particular noncentral chisquared distribution15 of d 2 H1 . Let c  6.0 be the cutoff for statistical significance of the
central chi-squared distribution with two degrees of freedom, as shown in Figure 2. The
power to detect the alternative positive effect is


Power   f ( x ) dx .
c

(5)

2.6 Required sample size
Sample size calculations allow investigators to plan study Ns so that there is a high
probability of detecting, as statistically significant, a biologically meaningful effect, if it
exists. For a particular alternative hypothesis, H1 , for example 1A= 0.2, 1B = 0.3, and
2A= 0.25, 2B = 0.35, one can determine the sample sizes (Ns) required to detect a
particular true effect with a particular probability or power. For simplicity the group size
for both intervention and control groups is assumed to be the same. By solving equations
(1) through (5) together for successive Ns, beginning with a very low value such as 10, a
computer program can quickly find the N required for the power to exceed a chosen target
value such as 0.90. In such calculations the true, population survival probabilities 1A , etc.
and the true population variances 1A (1-1A)/N1A , etc., are used in the place of the
sample-based expressions (1) and (2).
3. Results
3.1 Validation of test statistics under H0
In the theory just presented the test statistic, d2, should be distributed approximately as a
chi-squared distribution with two degrees of freedom under the null hypothesis. To obtain
a figure of merit for the goodness of approximation one can compute the tail probabilities
of the numerical vs. analytical d2 -distributions. Here we define the tail probability as the
area under the probability density function for values of d2 greater than 6. Histograms of
computer simulated results for 50,000 hypothetical clinical studies give a good
representation of the actual distribution of d2. When variance estimates (2a) and (2b) are
used to compute d2, the average tail probability for the d2 test statistic in 7 computer
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simulated scenarios in which the null hypothesis is true was 0.0580  0.0066 SD. This
result indicates that actual tail probability is slightly greater under the null hypothesis than
that which would be calculated using the chi-square distribution. However, when refined
variance estimates (2c) and (2d) are used to compute d2 , the average tail probability for the
d2 test statistic in the same 7 computer simulated scenarios was 0.0495  0.0018 SD (Table
1). The analytical tail probability from the central chi-squared distribution is 0.0498.
These results demonstrate that for group sizes typical in resuscitation research the actual
distribution of d2 under the null hypothesis is well approximated by a central chi-squared
distribution.
3.2 Sample calculations
Two dimensional significance testing is no more difficult than applying equations (1)
through (4) to readily available short-term and long-term survival data from a typical CPR
research study that is performed generally according to the Utstein guidelines 16-19.
Consider the hypothetical results for "new" vs. "old" CPR in Table 2. Short-term survival
for new CPR is an encouraging 39 percent vs. 25 percent for old CPR. However, the longterm survival is 10 percent for new CPR vs. 11 percent for old CPR. A conventional
interpretation of these data might be that although short-term results were encouraging, the
gold standard results for long-term survival showed no difference. The conclusion is that
the null hypothesis was probably true after all.
Analysis of joint survival leads to a different conclusion. First to compute d 2 it is
necessary to find the proportions of short-term survivors who also survive long-term, that
is, p2A = N2A /N1A and p2B = N2B/N1B. These proportions are different from the
conventional proportions of long-term survivors for the entire study, namely N 2A/NA and
N2B/N B. Then it is a simple matter to apply Equations (1) through (4) to compute d 2 , as
shown in Table 2.
Two-dimensional analysis using the d 2 test shows a significant deviation from the result
expected under the null hypothesis, for which we expect d2 < 6. In two-dimensional zspace, the outcome of the trial is represented by a point in the right lower quadrant of
Figure 1. With new CPR there is increased short-term survival and decreased survival
during the post-resuscitation interval. This result is, if you will, epinephrine-like, showing
some lingering toxicity. This two-dimensional statistical inference has consequences for
research planning. At first glance one would be tempted to abandon new CPR as
altogether ineffective and seek completely new strategies. After analysis of the joint
results, however, one would be inspired to modify new CPR to isolate the immediate
benefit and minimize the post-resuscitation toxicity.
3.3 Ns needed for significance
Table 3 presents sample (group) sizes for significance in a test of the null hypothesis with
90 percent power over a range of true treatment effects 1B and 2B. Here the group size

10

for both intervention and control groups is assumed to be the same: N A = N B = N. The first
row and first column of Table 3 show various alternative hypotheses in which survival
probabilities for the intervention group are actually greater than those for the control grou p.
For all control groups in Table 3 the probability of initial resuscitation is assumed to be 1/5
and the probability of surviving the post-resuscitation period is assumed to be 1/5 also, so
that the probability of long-term survival is (1/5) x (1/5) = 0.04. Various true treatment
effects are represented by the column and row values of 1B and 2B, each greater than 0.2.
Table entries are the numbers of patients needed to detect a given true effect with 90
percent power. Sample sizes were computed by exhaustive trial-and-error, beginning with
a minimal sample size of 10 patients in each group and incrementing the common Ns until
90 percent power is exceeded. Power is computed by numerical integration of the
probability density function for the appropriate non-central chi-squared distribution from 6
to infinity. Each value in Table 3 is the group size for a d2 test with 90 percent power
using combined short-term and long-term survival.
For comparison Table 4 gives corresponding sample sizes for a difference of proportions
test using long-term survival as the only endpoint. The long-term survival probabilities are
A = 1A 2A and B = 1B2B. Normalized differences in the proportions of survivors are
considered to be distributed as standard normal distributions with a mean under the null
hypothesis of zero and a mean under the alternative hypothesis of
B  A  A (1  A ) / N  B (1  B ) / N . In most scenarios fewer patients are needed to
reject the null hypothesis using the joint d2 test (Table 3) than when using a single test of
long-term survival (Table 4). In some cases half or fewer patients are needed using the
joint d2 test, compared to the one-dimensional z-test using long-term survival alone.
Exceptions occur if the intervention effect on immediate survival is small and the effect
during the post-resuscitation interval is somewhat larger. Then a combination of
immediate and post-resuscitation outcome has more noise than long-term outcome alone.
In this case the joint d 2 test requires larger Ns than a simple z-test of long-term survival.
For most other cases however, the joint test has greater power.
4. Discussion
Putative improvements in CPR that increase ROSC but leave survivors in lingering
vegetative states who never regain a semblance of health are not to be desired and would
substantially increase health care costs and family suffering. For this reason it is important
not to claim a good outcome of a randomized clinical trial of a new CPR technique without
improvement in long-term survival. However, the numbers of patients required for direct
statistical tests of long-term survival data are often prohibitively large, owing to the nature
of the binomial distribution and the statistical sampling thereof, especially when control
survival probability is low. It is possible, however, to use both short-term ROSC and postresuscitation survival together to test the null hypothesis with greater power. If this is done
in a way that ensures statistical independence of the initial resuscitation and postresuscitation results, then a simple and straightforward test using the chi-squared
probability distribution can be conducted.
11

One merely computes the test statistic d 2 = z 12 + z 22 for a study and compares the result to
the number 6. This approach is easy to present visually and tends to demystify the process
of two-dimensional, bivariate analysis, rendering it accessible to physician-scientists who
have had an introductory course in statistics. It is also a stronger and more conservative
test of the null hypothesis because it is able to detect biologically important mixed results,
such as increased probability of ROSC coupled with subsequent decreased probability of
surviving the post-resuscitation period. Such subtle, harmful effects in the postresuscitation phase might be missed with analysis of long-term survival alone. On the
other hand the d2 test is also more sensitive to true departures from the null hypothesis for
most plausible trial scenarios.
The method can also be extended to a meta-analysis of multiple studies of similar
interventions in a very straightforward way. For k studies of essentially the same
intervention that report both long term and short term data one merely adds together the z 12
and z 22 components in equation (3) from the various studies to get an expanded chisquared with 2k degrees of freedom. If a study lacks long-term data, a degree of freedom
can be subtracted. The result is distributed as a higher degree chi-squared under the null
hypothesis, which will have a cutoff value for rejecting the null hypothesis > 6, depending
on the degrees of freedom.
It is important to emphasize that proportion p 2 in the forgoing discussion is not equal to
conventional long-term survival (namely, the number of long term survivors divided by the
number randomized for each group) but instead the proportion of patients surviving shortterm that also survive long-term. This is a measure of the probability of surviving the postresuscitation period only. In this case statistical independence is assured.
Use of d2 test statistics that are distributed as noncentral chi-squared distributions when
there is a given true effect of the intervention allows for direct estimation of the power of a
study and also the N's required to demonstrate an expected treatment effect. If Table 3
does not suffice for planning of studies, a computer program embedded in an Excel
spreadsheet for evaluating the noncentral chi-squared distribution is available
electronically from the author upon request or can be written de novo without much
trouble.
The traditional discussion of outcomes in CPR research has been framed in terms of
"either-or". We should use either short-term or long-term survival as the primary endpoint
in resuscitation studies. Why not use both to extract the maximum amount of information
from hard-won clinical data? This approach may provide a way to satisfy both the shortterm and long-term camps debating the proper outcome measures of CPR studies and also
to save time, money, effort, and disappointment in clinical resuscitation research. Alfred
Hallstrom's idea that short-term and long-term survival data need to be considered jointly
is a good one.
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Tables
Table 1. Computer simulated tail probabilities for the d2 test statistic calculated using
variance estimates (2c) and (2d) in runs of 50,000 simulated clinical trials
N
200
100
50
25

=0.25
0.0490
0.0527
0.0488

=0.5
0.0484
0.0509
0.0475
0.0490

Common group size is N = NA = N B. Common survival probability is  = 1A = 1B = 2A
= 2B. The mean tail probability is 0.0495  0.0018 SD. Analytical tail probability for the
chi-square distribution is 0.0498.

Table 2. Hypothetical outcome data for a study of "new" CPR (group B) vs. "old" CPR
(group A) with NA = N B = 100 patients in each group

Group A
Group B

ROSC N1
25
39

Discharge
survivors N2
11
10

p1
0.25
0.39

p2
0.44
0.256

p3
0.11
0.10

Proportions: p1 = N 1/100, p2 = N1/N2 , p3 = N2 /100.
Statistics using simple variance estimates (2a) and (2b): z1 = 2.14, z2 = -1.48, d2 = 6.77.
Statistics using refined variance estimates (2c) and (2d): z1 = 2.11, z2 = -1.50, d2 = 6.71.
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Table 3. Sample size for significance in a test of H 0 when H1 is true using the d2 test of
joint short-term and long-term survival

1B
0.25
0.3
0.35
0.4
0.45
0.5

0.25
1001
454
218
128
84
59

0.3
982
388
201
122
81
58

2B
0.35
641
315
178
113
77
55

0.4
436
251
154
102
72
53

0.45
310
200
132
91
66
49

0.5
229
159
111
80
60
46

Table 4. Sample size for significance in a test of H 0 when H1 is true using a difference of
proportion test for long-term survivors

1B
0.25
0.3
0.35
0.4
0.45
0.5

0.25
1001
925
551
375
277
215

0.3
925
506
330
237
181
145

2B
0.35
551
330
226
167
131
106

0.4
375
237
167
127
100
82

0.45
277
181
131
100
80
66

0.5
215
145
106
82
66
54
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Figure 1. Graphical representation of two-dimensional survival analysis. Component test
statistics z1 and z2 represent normalized differences in immediate survival on the horizontal
axis and in post-resuscitation survival on the vertical axis. Joint test statistic, d2 , is the
square of the straight-line distance from the origin of the z 1 – z2 plane to a sample point
such as P1, representing the results of a particular study. Under the null hypothesis, H 0 ,
sample points such as P0 will tend to cluster about the origin (contour H 0). Under an
alternative hypothesis, H1 , sample points such as P1 cluster farther from the origin (contour
H1).
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Figure 2. Calculation of power from probability density distributions for the null
hypothesis, thin curve, and for an alternative hypothesis, thick curve. The critical value for
significance is x = 6.0. The area under the thick curve to the right of the critical value is
the power.
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